The Supreme Court is taking up the abortion pill
A series of rulings by the Supreme Court has restricted access to the drug Mifepristone, a medication typically used with misoprostol to bring about a medical abortion and to manage early miscarriage. Currently, the drug remains on the market, and any changes to the drug’s availability have been temporarily halted.
Legal Clarification and Judicial Access
Now, the Supreme Court has agreed to take up a case clarifying what changes are actually going to be made. This specific case would mark the first major abortion decision since the high court overturned Roe v. Wade last year.
Implications for the FDA and Public Health
The outcome would also have broader implications for the authority of the FDA, potentially challenging the ability of other agencies to protect health and safety.
Key Case Summary
- Medication: Mifepristone, typically used with misoprostol to bring about a medical abortion and to manage early miscarriage.
- Current Status: The drug remains on the market, and any changes have been temporarily halted.
- Judicial Context: The first major abortion decision since the high court overturned Roe v. Wade.
- Regulatory Impact: Broader implications for the authority of the FDA and other agencies.
Expert Insight
This article from Northeastern Global News gives insight into this historic case, featuring input from Northeastern’s Wendy Parmet (Law, Public Policy and Urban Affairs) and Daniel Urman (Law).